FDA warns ZIIP over quality-system violations and unapproved marketing of HALO 2.0, DOT, and gels.
What happened
FDA inspected ZIIP’s Pleasant Hill, CA facility from January 5 to January 12, 2026, and reviewed the website ziipbeauty.com. FDA found violations of the Quality System regulation (FDA’s manufacturing quality rules), including risk and complaint handling problems tied to reports of devices smoking, burning, or melting, and found Halo 2.0, DOT, and gels marketed without required clearances. FDA said ZIIP’s responses dated February 3 and May 15, 2026 were not adequate.
What FDA found
FDA says design verification did not show that design outputs met design inputs, with missing raw data, an undocumented firmware build, and no formal review of an external test report.
21 CFR 820.30(f)FDA says ZIIP’s risk analysis did not reflect complaints of overheating, smoking, burning, or melting and did not properly validate alternative gels.
21 CFR 820.30(g)FDA says CAPAs were closed without required effectiveness checks or evidence that the fixes worked.
21 CFR 820.100(a)FDA says app, firmware, and charging-port plug changes were made without proper documentation, review, or verification/validation.
21 CFR 820.30(i)FDA says 26 HALO complaints lacked investigation records or a documented reason not to investigate.
21 CFR 820.198(a)FDA says Halo 2.0, DOT, and the gels are marketed for new uses without required premarket approval/clearance and without 510(k) notification.
section 501(f)(1)(B), section 502(o), and section 510(k) of the Act
What FDA wants
FDA tells ZIIP that its responses are not adequate and that it must correct the cited quality-system, complaint, CAPA, design, and premarket violations; specific response deadlines are redacted in the letter.
Who should pay attention
- medical device companies with app and firmware design changes
- quality teams that use complaint data in risk analysis
- aesthetic device brands making unapproved claims
This is a summary. Read the original letter on fda.gov.